News | February 17, 2026
EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
Duvakitug was well tolerated and safety was consistent with the induction study
Iberdomide has the potential to be the first approved CELMoD agent
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
Subscribe To Our Newsletter & Stay Updated
